TUR-BT术后吡柔比星早期膀胱灌注预防肿瘤复发的临床观察

Observation of prophase intravesical instillation of pirarubicin(THP) in preventing non-invasive bladder cancer(BCa) relapse after transurethral resection of bladder(TUR-BT)

目的:探讨经尿道膀胱肿瘤电切术(TUR-BT)后吡柔比星(THP)早期膀胱灌注预防膀胱肿瘤复发的临床疗效。方法:回顾性分析2009年-2011年的142例非肌层浸润性膀胱肿瘤行TUR-BT患者资料,病例完全随机分为两组:A组(72例)为术后吡柔比星早期膀胱灌注组,B组(70例)为术后吡柔比星常规膀胱灌注组。术后定期复查及随访,监测患者并发症发生情况,两组随访期均为2年。结果:2年复发率:A组为8.3%,B组为21.4%,两组比较差异有统计学意义(P<0.05);两组均无明显的血尿常规异常、肝肾功能损害及全身不良反应;A组的短期尿路刺激症状发生率为20.8%,B组为18.6%,两组比较差异无统计学意义(P>0.05);A组的血尿发生率为8.3%,B组为5.7%,两组比较差异无统计学意义(P>0.05)。结论:TUR-BT术后吡柔比星早期膀胱灌注是预防膀胱肿瘤复发有效且安全的治疗方法。

Objective：Evaluating the effection of ProPhase intravascular instillation of TeP in Preventing from re-current BCa after TUR - BT. Methods：All 142 non - invasive BCa Patients were selected who were randomly chosen for ProPhase treatment（GrouP A）or regular intravascular treatment（GrouP B）after TUR - BT. The recurrent rate and side effects during last two years were monitored. Results：Recurrent rate in two years were 8. 3% for PhoPhase treat-ment,21. 4% for regular treatment（P ﹤ 0. 05）. No severe side effects and significant different（P ﹥ 0. 05）were ob-served between this two grouPs（hematuria：8. 3% for ProPhase treatment,5. 7% for regular treatment;bladder irrita-tion symPtoms：20. 8% for PhoPhase treatment,18. 6% for regular treatment）. Conclusion：ProPhase intravascular in-stillation treatment is an effective and safe method for non - invasive bladder cancer treatment after TUR - BT.